Lacrat

Ticagrelor, the active ingredient in Lacrat, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is indicated for patients with acute coronary syndrome, myocardial infarction and for the prevention of thrombotic cardiovascular events. GNH USA supplies Lacrat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ticagrelor is used in the management of platelet‑driven cardiovascular conditions. Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. Myocardial infarction: prevents recurrent ischemic events after an acute heart attack. Prevention of thrombotic cardiovascular events: lowers the incidence of clot‑related complications in high‑risk patients.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspnea: shortness of breath, often transient. - Bleeding: including bruising, nosebleeds, or gastrointestinal bleeding. - Headache: mild to moderate intensity. - Nausea or dyspepsia: gastrointestinal discomfort. - Dizziness or vertigo: sensation of light‑headedness. - Elevated serum uric acid: may precipitate gout in susceptible individuals.

Serious or Rare Side Effects: - Severe or life‑threatening bleeding: intracranial or fatal hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Anaphylactic or severe hypersensitivity reactions. - Hepatic injury: elevated transaminases or liver dysfunction. - Bradyarrhythmias: unusually slow heart rate. - Hyperkalemia: elevated blood potassium levels.

Before prescribing Ticagrelor, clinicians should consider several safety aspects. - Assess bleeding risk: evaluate history of hemorrhage, recent surgery or trauma. - Monitor renal function: dose adjustment may be needed in severe impairment. - Review concomitant antithrombotic therapy: avoid unnecessary combination with other anticoagulants. - Caution in patients with a history of asthma or COPD: dyspnea may be exacerbated. - Avoid use in patients with active pathological bleeding. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ticagrelor interacts with several drug classes that can modify its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ticagrelor plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Concurrent anticoagulants (warfarin, DOACs): markedly increase bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs, aspirin): additive bleeding risk. - Glycoprotein IIb/IIIa inhibitors: potentiate antiplatelet activity.

Moderate Interactions (Monitor Closely): - Statins metabolised by CYP3A4 (e.g., atorvastatin, simvastatin): may increase statin exposure. - Digoxin: ticagrelor can raise digoxin concentrations. - Calcium channel blockers (e.g., amlodipine): may modestly increase ticagrelor levels. - Proton pump inhibitors: potential effect on absorption, monitor efficacy.